Kyverna reports positive miv-cel autoimmune data
Kyverna Therapeutics (NASDAQ:KYTX) reported updated clinical data for its investigational CAR-T therapy miv-cel (mivocabtagene autoleucel) in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG).










